Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to ...

His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity ...

The MarketWatch News Department was not involved in the creation of this content. ATLANTA, Dec. 17, 2025 /PRNewswire/ -- Huxley Medical, Inc. today announced the U.S. Food and Drug Administration (FDA ...

The FDA clearance follows the presentation of SANSA clinical performance data earlier this year at the SLEEP meeting. The study, drawing on data collected from 325 patients across 7 clinical sites, ...

Lighthouse Medical Center announced the expansion of its regenerative medicine clinic as part of a broader initiative to strengthen clinical infrastructure and support physician-directed regenerative ...

Every medicine commercial always acts like its so perfect while speed reading fatal side effects :) #legendaryjay #parody #comedy Steven Spielberg’s "Disclosure Day" drop has everyone saying the same ...

I’m ticked off that a new medication commercial on TV says, “Do not take if you are allergic to this.” How are you supposed to know if you are allergic unless you take it? I am concerned about the ...

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading biotechnology company specializing in tools and technologies for the development of induced pluripotent stem cell (iPSC)-based ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA HAFYERA contains the active ingredient paliperidone palmitate.

With 80% of FDA approvals now classified as specialty products, commercial teams must rethink how they bring medicines to market, said Matt Lehmann, executive vice president, Global Commercial ...

17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of ...

21 abstracts from across the Company's portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and schizophrenia New Phase 3 data demonstrate the ...